Modena, Merk Cancer Vaccine Reduced Melanoma Recurrence by 44%
Moderna (NASDAQ: MRNA) has developed an experimental personalized melanoma vaccine, which along with Merck & Co’s blockbuster immunotherapy Keytruda cut the risk of the skin cancer’s reappearance or death by 44% in comparison with only Keytruda. [stock_market_widget type=”inline-label” template=”basic9″ color=”orange” assets=”MRNA” api=”yf”] [stock_market_widget type=”chart” template=”basic” color=”orange” assets=”MRNA” range=”1mo” interval=”1d” axes=”true” cursor=”true” api=”yf” style=”width: 100%; height: …
Modena, Merk Cancer Vaccine Reduced Melanoma Recurrence by 44% Read More »